Philogen Logo

Philogen

PHIL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005373789 (+1 more)
LEI:
81560009EA1577917768
Country:
Italy
Address:
PIAZZA LA LIZZA, 7, 53100 SIENA
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Philogen is a fully-integrated, clinical-stage biotechnology company founded in 1996. It specializes in the discovery and development of innovative biopharmaceuticals for the targeted treatment of cancer, chronic inflammatory diseases, and other serious conditions associated with angiogenesis. The company's proprietary technology platform enables the creation of novel antibody-based therapeutics, such as immunocytokines, designed to selectively deliver therapeutic agents to the site of disease. Philogen's capabilities span from research and discovery through to GMP manufacturing and clinical development of its pipeline products.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Philogen. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-18 20:02
M&A Activity
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
Italian 213.9 KB
2025-07-07 16:50
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
Italian 153.0 KB
2025-07-07 12:08
Regulatory News Service
Allegato 3F
Italian 26.7 KB
2025-06-30 17:04
Transaction in Own Shares
2025 06 30 - CS settimanale acquisto azioni proprie
Italian 181.7 KB
2025-06-25 12:29
Legal Proceedings Report
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in…
English 180.5 KB
2025-06-11 01:34
Regulatory News Service
Press Release Licenza OncoACP3 (Price Sensitive)
Italian 225.0 KB
2025-06-03 13:40
Transaction in Own Shares
2025 06 03 - CS settimanale acquisto azioni proprie
Italian 144.1 KB
2025-05-26 17:46
Registration Form
Statuto
Italian 261.6 KB
2025-05-26 17:24
Post-Annual General Meeting Information
Deposito del Verbale dell'Assemblea degli Azionisti
Italian 131.0 KB
2025-05-26 17:22
Pre-Annual General Meeting Information
Verbale dei lavori dell'Assemblea Ordinaria e Straordinaria degli Azionisti
Italian 30.4 MB
2025-05-26 15:09
Transaction in Own Shares
2025 05 26 - CS settimanale acquisto azioni proprie
Italian 147.5 KB
2025-05-19 12:24
Transaction in Own Shares
2025 05 19 - CS settimanale acquisto azioni proprie
Italian 130.7 KB
2025-05-12 15:04
Transaction in Own Shares
2025 05 12 - CS settimanale acquisto azioni proprie
Italian 141.2 KB
2025-05-07 10:30
Director's Dealing
Allegato 3F
Italian 27.5 KB
2025-05-06 18:56
Post-Annual General Meeting Information
Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa…
Italian 259.8 KB

Automate Your Workflow. Get a real-time feed of all Philogen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Philogen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Spago Nanomedical AB Logo
Develops nanomedicine for precision MRI tumor diagnostics and targeted cancer radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Developing first-in-class macrocyclic drugs for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops and out-licenses preclinical cancer drug programs using fragment-based discovery.
Sweden SPRINT
Stayble Therapeutics AB Logo
Develops an injectable therapy for disc-related spinal disorders as an alternative to surgery.
Sweden STABL
Stem Cells Spin Spolka Akcyjna Logo
Commercializes patented MIC-1 stem cell technology for regenerative medicine.
Poland SCS
STRIX GROUP PLC Logo Isle of Man KETL
SynAct Pharma Logo
Developing oral resolution therapies for inflammatory diseases like rheumatoid arthritis.
Sweden SYNACT
SYNAIRGEN PLC Logo
Develops an inhaled interferon beta therapy for severe viral lung infections.
United Kingdom SNG
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT
Israel TMIS